Glossary
- Accelerated development and introduction plans (ADIPs)
- Accelerated development and introduction plans are time-limited programs designed to address challenges to making available new life-saving vaccines in developing countries. The aim of an ADIP is to shorten the time lag between a vaccine being proven to be safe and effective for use and its development for specific introduction in poor countries. In June 2002, the GAVI Board endorsed the creation of two ADIPs: the "Rotavirus Vaccine Program" and the "PneumoADIP".
Working with GAVI, WHO, the vaccine industry, and other partners, the ADIPs support the
establishment of surveillance systems, conduct cost-effectiveness analyses, support demand
forecasting, and engage in both global and country level advocacy. During 2008, focus will shift from vaccine development to introduction. - Advance market commitment (AMC)
- An advance market commitment provides a way of accelerating the discovery and manufacture of
vaccines. It is based on the concept of putting money aside to guarantee the purchase of
vaccines once they are developed, providing that they meet stringent, pre-agreed criteria on
effectiveness, cost, and availability, and that developing countries demand them. The aim is to
stimulate investment in research, development, and the establishment of manufacturing facilities,
while giving governments in developing countries control over which vaccines they need.
By guaranteeing an affordable long-term price, often referred to as the tail price, the AMC
supports sustained use of the vaccine. In 2007, GAVI began working with partners on a US$ 1.5
billion AMC pilot to fund the introduction of suitable pneumococcal vaccines in GAVI-eligible
countries. For more information, please visit www.vaccineamc.org.
- Annual progress report (APR)
- Countries provide an annual progress report to the GAVI Secretariat by 15 May each year. GAVI
relies upon annual progress reports to monitor and evaluate the use of GAVI support in all eligible
countries. This single tool provides a comprehensive framework for reporting on all GAVI
programmes, and allows countries to flexibly modify planning for subsequent years. Annual
progress reports are required for continued support. The Independent Review Committee
reviews each report to determine whether funding should continue and if adjustments are
needed. Before submission for review, each report is screened by in-country partners and
certified by each country’s Interagency Coordinating Committee.
- Antigen
- An antigen is the active component of a vaccine which stimulates the body to produce the
antibodies which fight off disease.
- Auto-disable syringes (AD syringes)
- Autodisable syringes are single-use syringes with a blocking mechanism to prevent their re-use
and thus support immunisation safety. GAVI has supported the use of autodisable syringes as a
principal strategy within injection safety.
- Birth cohort
- The birth cohort is the number of children born in a country in a given year.
- Buffer stock
- A buffer stock is an additional stock of vaccine that enables countries to respond rapidly to
distribution irregularities and unplanned events. To ensure that countries have sufficient vaccines,
the buffer stock is normally assumed to be 25% of the vaccine requirements (three months’
supply) for any given year. All new and underused vaccines support from GAVI takes into
account the need for a buffer stock of vaccines.
- Burden of disease
- The burden of disease refers to the magnitude of a health problem in an area, measured by
mortality (deaths), morbidity (persons affected by disease or illness), and other indicators such as
permanent disability. Knowledge of the burden of disease can help determine where investment
in health interventions and systems should be targeted. Disease burden studies are carried out at
global, regional, and national levels to guide vaccine investment policy and introduction decisions.
- Campaign
- Vaccination campaigns offer additional opportunities to reach the unimmunised. They are part of
a range of immunisation strategies that reach beyond the usual parameters of routine
immunisation programmes (such as number of doses or target population age). They have the
objective of accelerating the immunisation of a large group of individuals in a limited timeframe of
days or weeks. Campaigns rapidly reduce the person-to-person transmission of some contagious
diseases, and are an effective adjunct to routine immunisation for accelerating disease control
efforts. "Catch-up" campaigns or other immunisation strategies target a previously unimmunised
population at risk for illness or disease outbreaks.
- Children’s Vaccine Initiative (CVI)
- Founded after the World Summit for Children in September 1990, the Children’s Vaccine Initiative
had three goals: 1) the immunisation of all children; 2) research to determine the feasibility of a
single-dose multivalent vaccine; and 3) introduction of new vaccines for infectious diseases. CVI
was the predecessor to the GAVI Alliance.
- Civil society organisation (CSO)
- Civil society organisations include nongovernmental organisations, community-based groups,
academic institutions, professional organisations, faith-based organisations, women’s
organisations, technical institutes, and research institutions. Recognising the key role that CSOs
play in immunisation and child health, in 2005, the GAVI Board decided to strengthen the
involvement of CSOs in the GAVI Alliance. Since 2007, two types of support for CSOs have
been available: Type A is a lump sum each country can apply for and use for strengthening CSO
collaboration and representation at country and international levels. Type B support is available to
10 countries in the 2007–2009 pilot phase, providing a direct funding opportunity for CSOs in
these countries. A CSO constituency is evolving with representatives from global, national, and
local CSOs.
- Co-financing
- Co-financing, introduced by GAVI in 2007, means countries share the cost of the vaccines supplied by the GAVI Alliance. The intention is to ensure immunisation programmes are sustainable in the long-term. GAVI-eligible countries have been grouped according to their expected ability to pay, and the co-financing levels vary across the different groups.
- Cold chain
- The cold chain is a system of refrigeration used for keeping and distributing vaccines at the
correct temperature and in good condition, from the manufacturer to the point of use by the health
worker. This consists of a series of cold storage and transport links, such as refrigerators, cold
boxes, and vaccine carriers with cool packs, all designed to keep the vaccine at appropriate
temperatures so that it remains sterile and potent until it reaches the user. Most vaccines should
be kept at between 2-8°C and while some can be damaged by freezing, others can be damaged
by excessive heat. All GAVI-supplied vaccines are equipped with vaccine vial monitors (VVMs) so
that vaccines which have gone outside of the acceptable temperature range are not used.
- Combination vaccine
- Combination vaccines are formulated with antigens against several infectious agents or
pathogens in one injection (for example DTP, DTP-HepB, or DTP-HepB+Hib).
- Comprehensive multi-year plan for immunisation (cMYP)
- This is a single plan which consolidates several immunisation activities. It is a key planning and
management tool for national immunisation programmes. It addresses global, national, and
subnational immunisation objectives and strategies, and evaluates the costs and financing of the
programme in line with the WHO-UNICEF Global Immunization Vision and Strategy 2006-2015.
GAVI requires countries to submit a cMYP along with the standard proposal form when applying
for GAVI support (ISS, INS, and NVS). In 2006, over 50 countries had developed cMYPs using
the WHO-UNICEF cMYP guidelines and costing tool. The cMYP replaces the Financial
Sustainability Plan.
- Conjugate vaccine
- This is a vaccine that is formulated by chemically linking sugar chains derived from the pathogen
to a protein backbone. Conjugate vaccines supported by GAVI include Hib and pneumococcal
vaccines.
- Data quality audit (DQA)
- The DQA was designed to verify reported performance as well as improve immunisation
monitoring and reporting systems. It reviews the records of number of children vaccinated in
order to estimate the accuracy of the Expanded Programme on Immunization (EPI) reporting
system. In order to receive the reward element of GAVI’s Immunisation Services Support (ISS),
countries must demonstrate both an increase in the number of additional infants immunised
compared to the previous year and have passed a data quality audit.
- Developing Country Vaccine Manufacturers Network (DCVMN)
- The DCVMN is a global group of vaccine producers from developing and middle-income
countries which exists to facilitate networking and collaboration. It is represented by one seat on
the GAVI Alliance Board.
- Diphtheria, tetanus and pertussis vaccine (DTP)
- Three combined doses of diphtheria-tetanus-pertussis vaccine are usually provided in the first six
months of life according to national immunisation schedules. Coverage with the third dose of
DTP, known as DTP3, is an indicator used by the World Health Organization and GAVI as a
measure of immunisation programme strength. One of GAVI’s goals is for all countries to achieve
routine immunisation coverage (DTP3) of 90% nationally with at least 80% coverage in every
district by 2010.
- Direct government funding
- Cash received directly from government donors is channeled into the GAVI Fund Account or a
World Bank Trust Account being held on behalf of the GAVI Fund. Government contributions are
increasingly being made on a multi-year basis. Through both its government funding and its
innovative financing mechanisms, GAVI seeks to secure a robust, predictable, multi-year funding
base sufficient to meet long term commitments made to GAVI-eligible countries.
- Eligible country (also "GAVI-eligible country")
- There are 72 countries with a GNI per capita of US$ 1000 or less in 2003 which are eligible to
apply for GAVI support. For a list of the currently eligible countries please click here. For Health
System Strengthening (HSS) and certain types of new vaccine support, additional criteria apply,
and therefore not all GAVI-eligible countries qualify for these types of support.
- Evaluation
- Evaluation requires a systematic and objective assessment of design, implementation, and
results. The main objective of evaluation at GAVI is to improve the performance of GAVI
operations and policies by incorporation of lessons learnt into the decision-making process.
- Every Child Council
- The Every Child Council, an honourary group, was established in 2007 to support the work of
GAVI’s private philanthropy effort, the "Immunize Every Child Campaign." It includes individuals
from public and private life who have made or secured significant financial commitments to
support the immunisation cause.
- Expanded Program on Immunization (EPI)
- Since its inception in 1974, the Expanded Programme on Immunization has brought together
partners under the auspices of the World Health Organization to increase immunisation coverage from the then low levels of 5% to the current levels, which are close to 80%. The traditional EPI vaccines are BCG (Bacille Calmette-Guérin, against tuberculosis), DTP (against diphtheria, tetanus, and pertussis), oral polio vaccine (OPV), and measles.